🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05997693
Recruiting Phase 3

One-Month DAPT in CABG Patients

NCT05997693 · tracked via the Priya Life Science China tracker
Sponsor
Weill Medical College of Cornell University
Phase
Phase 3
Started
2024-08-15
Last updated
2025-12-22

Condition(s) studied

Chronic Coronary Disease

Investigational drug(s) / intervention(s)

Ticagrelor 90 MGLow-dose aspirin

Ticagrelor 90 MG: Ticagrelor 90 mg twice daily taken orally for one month

Low-dose aspirin: 75-150 mg once daily taken orally

Study summary

The purpose of this study is to compare the effect of ticagrelor plus low-dose aspirin versus low-dose aspirin alone in patients with chronic coronary disease undergoing coronary artery bypass grafting.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years * Elective first-time CABG with use of ≥1 saphenous vein graft; * Ability to sign informed consent and comply with all study procedures, including follow-up for at least 5 years. Exclusion Criteria: * Any indication for dual antiplatelet therapy, including * Acute/recent (within 1 year) ACS (NSTE-ACS or STEMI) * Recent PCI requiring continuation of dual antiplatelet therapy after CABG * Current or anticipated use of oral anticoagulation; * Paroxysmal, persistent or permanent atrial fibrillation; * Any concomitant cardiac or non-cardiac procedure; * Planned cardiac or non-cardiac surgery within one year; * Preoperative end-organ dysfunction (dialysis, moderate to severe liver failure, respiratory failure), cancer or other non-cardiac comorbidity with a life expectancy \<5 years; * Inability to use the saphenous vein; * Contraindications to the use of aspirin; * Contraindications to the use of ticagrelor, including * Known hypersensitivity to ticagrelor * Active pathological bleeding (including, but not limited to gastrointestinal or intracranial bleeding) * History of intracranial hemorrhage * Concomitant therapy with strong CYP3A4 inhibitors (eg ketoconazole, clarithromycin, nefazodone, ritonavir, atazanavir) * Inability to undergo coronary computed tomographic angiography (CCTA); * Participating in another investigational device or drug study; * Women of childbearing potential * Any major perioperative complication including, but not limited to, stroke, TIA, MI, CABG-related bleeding (BARC type 4), sepsis.

Primary outcome measure(s)

Trial sites (22)

FacilityCityRegionStatus
Englewood Hospital Englewood New Jersey Recruiting
NewYork-Presbyterian: Queens Hospital Flushing New York Recruiting
Weill Cornell Medicine New York New York Recruiting
Medical University Innsbruck Innsbruck Innsbruck Recruiting
Medical University Graz Graz Austria Recruiting
Johannes Kepler University Linz Linz Austria Recruiting
Medical University of Vienna Vienna Austria Recruiting
University of Ottawa Heart Institute Ottawa Ontario Not Yet Recruiting
Ruijin Hospital: Shanghai Jiao Tong University School of Medicine Shanghai China Recruiting
Jilin Heart Hospital Changchun Jilian Recruiting
Beijing Anzhen Hospital Beijing China Recruiting
Center China Fuwai Hospital Beijing China Recruiting
University Hospital of Düsseldorf Düsseldorf Germany Recruiting
Westdeutsches Herz- und Gefäßzentrum Essen, Universität Duisburg-Essen Essen Germany Not Yet Recruiting
Klinik für Herz- und Gefäßchirurgie - Universitäts-Herzzentrum Freiburg - Bad Krozingen Freiburg im Breisgau Germany Recruiting
University Hospital Giessen Giessen Germany Recruiting
Jena University Hospital Jena Germany Recruiting
LMU Klinikum Campus Großhadern München Germany Not Yet Recruiting
Robert-Bosch-Krankenhaus Stuttgart Stuttgart Germany Not Yet Recruiting
Sahlgrenska University Hospital Gothenburg Sweden Recruiting
Sahlgrenska University Hospital Sweden Gothenburg Sweden Not Yet Recruiting
Skåne University Hospital Malmö Sweden Recruiting

More Weill Medical College of Cornell University trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05997693 on ClinicalTrials.gov ↗ ← All trials in China